Short course radical cure for vivax malaria in Nepal - a randomized controlled trial

20 Nov 2019

Chief investigator: Dr Kamala Ley-Thriemer; Investigators: Dr Prakash Ghimire, Tribhuvan University, Nepal Dr Bibek Lal, National Malaria Control Program, Department of Health Services, Ministry of Health and Population, Nepal Dr Benedikt Ley, Menzies School of Health Research Professor Ric Price, Menzies School of Health Research

Study title:

Short course radical cure of P. vivax in Nepal - a randomized controlled trial – pilot study.

Aims:

Assess the efficacy of a 7-day low dose course of primaquine (3.5mg/kg total dose) for the radical cure of P. vivax malaria in mixed malaria infections.

Objectives:

Primary:

To assess the safety and efficacy of a 7-day course of primaquine in preventing recurrent symptomatic P. vivax in G6PD normal patients following uncomplicated P. vivax and P. falciparum malaria.

Secondary:

To assess the efficacy of a 7-day course of primaquine in preventing recurrent symptomatic and asymptomatic P. vivax parasitaemia
To assess the safety of a 7-day course of primaquine treatment

For more information visit the clinical trials website.

Project dates:

The trial will commence in March 2020.